For US Residents Only

How PLUVICTO Works

Prescribing Information

Live Support Is Available

Call Novartis Patient Support at

1-888-NOW-NOVA
(1-888-669-6682)

Mon-Fri: 8 AM-8 PM ET

Live Support Is Available

Call Novartis Patient Support at

1-888-NOW-NOVA
(1-888-669-6682)

Mon-Fri: 8 AM-8 PM ET

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased ris...

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:

has spread to other parts of the body (metastatic), and
has...

< Back To Site

PLUVICTO is the first and only approved PSMA-targeted radioligand therapy

PLUVICTO is targeted therapy

PLUVICTO is a targeted therapy that delivers radiation treatment directly to PSMA+ cells.

1. PSMA is a biomarker that is expressed on prostate cancer cells and can be seen on a PSMA PET scan. PLUVICTO can be used to target PSMA-positive cancer cells.

2. Once PLUVICTO attaches to PSMA, it is absorbed by the cell.

3. Once PLUVICTO is absorbed by the cell, it releases radiation that can damage and kill cells that are PSMA+ and other nearby cells.

PSMA+, prostate-specific membrane antigen positive.

Next: How PLUVICTO May Help